STOCK TITAN

T. Rowe Price (IMCR) holds 1.89M ADRs, files Schedule 13G/A amendment

(Moderate)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

T. Rowe Price Investment Management, Inc. filed an amendment to a Schedule 13G reporting beneficial ownership of 1,891,600 ADRs of Immunocore Holdings plc, representing 3.7% of the class. The filing lists sole voting and dispositive power over the reported shares and includes a signed declaration dated 05/15/2026.

The filing affirms ownership is 5% or less and contains a customary denial that the filer is the beneficial owner. No transaction details or purchase/sale directions are reported in this excerpt.

Positive

  • None.

Negative

  • None.

Insights

Large asset manager reports a passive stake below the 5% reporting threshold.

The amendment lists 1,891,600 ADRs (3.7%) with sole voting and dispositive power, consistent with an institutional position reported on Schedule 13G. The filing's language and the 5% or less statement indicate passive investment status rather than an active control intent.

Holder decisions will determine future disclosure; subsequent amendments would appear if ownership crosses regulatory thresholds or the filer changes intent.

Beneficial ownership 1,891,600 ADRs Amount beneficially owned as reported in Item 4(a)
Percent of class 3.7% Percent of class reported in Item 4(b)
Signature date 05/15/2026 Signed declaration date at the end of the filing
Schedule 13G/A regulatory
"amendment to a Schedule 13G reporting beneficial ownership"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
beneficial ownership financial
"Amount beneficially owned: 1891600 (b) Percent of class: 3.7 %"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
sole dispositive power regulatory
"Sole Dispositive Power 1,891,600.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What stake does T. Rowe Price report in IMCR?

T. Rowe Price reports beneficial ownership of 1,891,600 ADRs, equal to 3.7% of Immunocore Holdings plc's ADR class, as stated in the amendment filed and signed on 05/15/2026. The filing lists sole voting and dispositive power over these ADRs.

Does this Schedule 13G/A indicate active control of Immunocore?

No. The filing is an amendment on Schedule 13G and states ownership of 5% or less, which is consistent with a passive investor reporting status rather than an intent to exert control or influence over corporate governance.

What voting and disposition powers does T. Rowe Price report?

The amendment states sole voting power for 1,891,600 ADRs and sole dispositive power for the same number, with 0 shared voting or dispositive power listed in the filing's ownership table.

When was the Schedule 13G/A amendment signed?

The amendment bears a signature dated 05/15/2026, signed by Ellen York as Vice President for T. Rowe Price Investment Management, Inc., per the closing signature block in the provided excerpt.

Will future transactions require updated disclosures by T. Rowe Price?

If the holder's classification or ownership threshold changes, subsequent amendments would be required. The filing here reflects passive ownership at 3.7%; any increase above reportable thresholds or change in intent must be disclosed in later filings.





45258D105

(CUSIP Number)
03/31/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G



T. Rowe Price Investment Management, Inc.
Signature:Ellen York
Name/Title:Vice President
Date:05/15/2026